GO:0051055 negative regulation of lipid biosynthetic process: Lipogenesis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051055 describes any process that stops, prevents, or reduces the frequency, rate or extent of lipid biosynthesis.
• Key negative regulators include SCD1 inhibition, NCOA4-mediated ferritinophagy, and intestine-derived exosomes that suppress hepatic lipogenesis [1,6].
• Dysregulation of this process contributes to fatty liver disease, insulin resistance, and cancer progression [4,5].
• Microbial factors such as YhcB loss can overactivate fatty acid biosynthesis, highlighting conserved control nodes.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators [1,4,5].
• Targeting negative regulators of lipogenesis is a promising therapeutic strategy in oncology and metabolic disease [1,5].
Description
Lipids are essential for membrane integrity, energy storage, and signaling, but their overproduction drives pathologies ranging from nonalcoholic fatty liver disease to cancer [4,5]. The Gene Ontology term GO:0051055, negative regulation of lipid biosynthetic process, captures the cellular mechanisms that restrain lipogenesis. This process is not a single pathway but a network of transcriptional, post-transcriptional, and metabolic checkpoints that ensure lipid synthesis matches physiological demand [6,8]. Understanding these brakes is critical because their failure leads to lipid accumulation and metabolic dysfunction [4,5]. In cancer, for example, salidroside sensitizes triple-negative breast cancer to ferroptosis by modulating SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy, directly linking negative regulation of lipid biosynthesis to therapeutic vulnerability. Similarly, hepatocyte Smoothened activity controls susceptibility to insulin resistance and nonalcoholic fatty liver disease, underscoring the clinical relevance of lipogenic control. This article integrates authoritative GO annotations with verified PubMed literature to provide a research-grade overview of GO:0051055, its molecular players, disease connections, and experimental strategies.
negative regulation of lipid biosynthetic process At A Glance
| GO ID | GO:0051055 |
|---|---|
| GO term | negative regulation of lipid biosynthetic process |
| Ontology | biological_process |
| Synonym | down regulation of lipid biosynthetic process; inhibition of lipid biosynthetic process; negative regulation of lipid anabolism; negative regulation of lipid biosynthesis; negative regulation of lipid formation; negative regulation of lipid synthesis; negative regulation of lipogenesis |
| Major function | Restrains the rate of lipid biosynthesis to maintain metabolic homeostasis |
| Key regulators | SCD1, NCOA4, Smoothened, ketohexokinase-C, YhcB, intestine-derived exosomes |
| Associated diseases | Nonalcoholic fatty liver disease, insulin resistance, triple-negative breast cancer, acne |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, lipidomics, ferroptosis assays |
What Is GO:0051055?
GO:0051055, negative regulation of lipid biosynthetic process, is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. It encompasses inhibition of lipid anabolism, biosynthesis, formation, synthesis, and lipogenesis. This regulation can occur at multiple levels, including enzyme inhibition, transcriptional repression, and degradation of lipogenic enzymes or substrates.
Why Is negative regulation of lipid biosynthetic process Important in Cell Biology?
Negative regulation of lipid biosynthetic process is essential for preventing lipotoxicity and maintaining energy balance. Its dysregulation is a hallmark of metabolic disorders such as nonalcoholic fatty liver disease and insulin resistance, and it influences cancer cell survival by modulating ferroptosis sensitivity [1,4,5]. Understanding this process provides mechanistic insights into disease pathogenesis and identifies targets for therapeutic intervention.
• Prevents excessive lipid accumulation that leads to steatosis and lipotoxicity.
• Modulates ferroptosis sensitivity in cancer cells, offering a therapeutic strategy.
• Controls hepatic insulin sensitivity and susceptibility to nonalcoholic fatty liver disease.
• Influences gut microbiota-host interactions and obesity-related metabolic inflammation.
• Regulates sebum production and acne pathogenesis through diet-metabolomics links.
• Conserved bacterial mechanisms, such as YhcB loss, reveal fundamental control nodes.
• Essential for membrane lipid homeostasis and cellular stress responses.
• Provides targets for CRISPR-based functional genomics in metabolic disease research [1,4,5].
What Happens During negative regulation of lipid biosynthetic process?
Transcriptional repression of lipogenic genes
In simple terms: The cell turns down the instructions for making fat-making enzymes.
Negative regulation often begins with reduced transcription of genes encoding lipogenic enzymes such as fatty acid synthase and stearoyl-CoA desaturase 1 (SCD1). In triple-negative breast cancer, salidroside modulates SCD1-mediated lipogenesis, leading to decreased lipid biosynthesis and increased ferroptosis sensitivity. Similarly, hepatocyte Smoothened activity controls the expression of lipogenic programs, and its inhibition protects against insulin resistance and nonalcoholic fatty liver disease.
Post-translational inhibition and degradation of lipogenic enzymes
In simple terms: Existing fat-making enzymes are blocked or destroyed.
Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation, indirectly affecting lipid biosynthesis. NCOA4-mediated ferritinophagy can alter iron availability and lipid peroxidation, impacting lipogenesis and ferroptosis. In bacteria, loss of YhcB results in overactive fatty acid biosynthesis, indicating that YhcB normally restrains this pathway.
Extracellular signals and inter-organ communication
In simple terms: Messages from other organs or the environment tell the cell to stop making fat.
Intestine epithelium-derived exosomes regulate hepatic lipid metabolism, demonstrating that negative regulation of lipid biosynthesis can be mediated by inter-organ vesicular communication. Diet-derived metabolites and gut microbiota also influence host lipid synthesis, as reviewed in the context of obesity and acne [2,3].
Feedback inhibition by lipid intermediates
In simple terms: Building blocks of fat can shut down their own production when they pile up.
Essential lipid A enzymes in bacteria are subject to feedback inhibition and regulation, illustrating conserved mechanisms where end-products or intermediates suppress their own biosynthetic pathways. Such feedback loops are critical for maintaining lipid homeostasis and preventing overproduction.
Key Genes Involved in GO:0051055 negative regulation of lipid biosynthetic process
The following genes and proteins are experimentally validated participants in negative regulation of lipid biosynthetic process, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCD1 | Catalyzes desaturation of fatty acids; its inhibition reduces lipogenesis | Target in triple-negative breast cancer ferroptosis sensitization |
| NCOA4 | Mediates ferritinophagy, affecting iron and lipid peroxidation | Modulates ferroptosis and lipid biosynthesis in cancer |
| SMO | Hedgehog signaling component; hepatocyte Smoothened activity controls lipogenesis | Determines susceptibility to insulin resistance and NAFLD |
| KHK-C | Regulates protein acetylation and CPT1a-mediated fatty acid oxidation | Links fructose metabolism to lipid biosynthesis |
| YhcB | Bacterial protein; its loss overactivates fatty acid biosynthesis | Model for conserved negative regulation |
| CPT1A | Rate-limiting enzyme for fatty acid oxidation; affected by acetylation | Indirectly influences lipid biosynthesis |
| LIPID A enzymes | Essential for lipid A biosynthesis; subject to inhibition | Antibacterial target and model for feedback regulation |
| Exosomal cargo | Intestine-derived exosomes regulate hepatic lipid metabolism | Inter-organ communication in lipid homeostasis |
| Gut microbiota | Modulates host lipid metabolism and obesity | Diet-microbiome-host interactions |
| Dietary factors | Influence acne metabolomics and lipogenesis | Link between diet and sebum production |
How Is negative regulation of lipid biosynthetic process Regulated?
Negative regulation of lipid biosynthetic process is controlled by a network of signaling pathways, including Hedgehog signaling through Smoothened, insulin signaling, and nutrient-sensing pathways such as mTOR. Ketohexokinase-C alters global protein acetylation to modulate CPT1a activity, thereby affecting lipid oxidation and biosynthesis. Intestine-derived exosomes provide endocrine-like regulation of hepatic lipid metabolism. Additionally, feedback inhibition by lipid intermediates, as seen in lipid A biosynthesis, represents an ancient regulatory mechanism.
negative regulation of lipid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SCD1 | Triple-negative breast cancer, ferroptosis | CRISPR knockout in MDA-MB-231 cells |
| SMO | Nonalcoholic fatty liver disease, insulin resistance | Hepatocyte-specific knockout mice |
| KHK-C | Hepatic steatosis, fructose metabolism | Liver-specific knockout or overexpression |
| NCOA4 | Ferroptosis, iron metabolism | Knockout in cancer cell lines |
| YhcB | Bacterial fatty acid overproduction | E. coli deletion mutants |
Nonalcoholic fatty liver disease and insulin resistance
Hepatocyte Smoothened activity controls susceptibility to insulin resistance and nonalcoholic fatty liver disease, and its dysregulation leads to excessive hepatic lipid accumulation. Ketohexokinase-C-mediated regulation of protein acetylation and CPT1a affects fatty acid oxidation, contributing to steatosis. Intestine-derived exosomes also regulate hepatic lipid metabolism, linking gut function to liver disease.
Cancer and ferroptosis
In triple-negative breast cancer, salidroside sensitizes cells to ferroptosis by modulating SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. This highlights how negative regulation of lipid biosynthesis can be exploited to induce ferroptotic cell death in cancers dependent on lipogenesis.
Acne and sebum production
Dietary factors influence acne metabolomics, inflammation, and comedogenesis, partly through effects on sebum lipid biosynthesis. Negative regulation of lipid biosynthetic process in sebocytes may be a target for acne therapy.
Obesity and gut microbiota
Diet, gut microbiota, and host genetics interact to regulate lipid metabolism and obesity. Microbial factors such as YhcB in bacteria demonstrate conserved mechanisms of fatty acid biosynthesis regulation.
From negative regulation of lipid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SCD1 increase ferroptosis sensitivity? | CRISPR knockout of SCD1 in triple-negative breast cancer cells |
| Does hepatocyte Smoothened inhibition protect against NAFLD? | Liver-specific Smo knockout mice |
| How does KHK-C acetylation affect CPT1a and lipid oxidation? | KHK-C knockout hepatocytes and acetylation mimics |
| Do intestine-derived exosomes suppress hepatic lipogenesis? | Exosome treatment in hepatocyte cultures and mouse models |
| What is the role of YhcB in bacterial fatty acid synthesis? | YhcB deletion strains and lipid profiling |
| Can point mutations in lipid A enzymes alter feedback inhibition? | Site-directed mutagenesis and enzyme assays |
How to Study the negative regulation of lipid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on lipid biosynthesis | Identify negative regulators |
| Lipidomics | Lipid species abundance | Quantify lipogenesis changes [1,4] |
| RNA-seq | Transcriptional changes | Assess lipogenic gene expression |
| Proteomics | Protein abundance and modifications | Detect acetylation changes |
| Ferroptosis assay | Lipid peroxidation and cell death | Link lipogenesis to ferroptosis |
| Insulin sensitivity test | Glucose uptake and signaling | Evaluate NAFLD models |
| Exosome isolation | Vesicle-mediated regulation | Study inter-organ communication |
| Bacterial genetics | Fatty acid synthesis flux | Model conserved regulation |
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify negative regulators of lipid biosynthetic process. For example, knocking out candidate genes such as SCD1 or NCOA4 followed by lipidomics or ferroptosis assays reveals their roles.
Lipidomics and metabolomics
Mass spectrometry-based lipidomics quantifies changes in lipid species upon genetic or pharmacological perturbation, providing direct evidence of altered lipogenesis [1,4].
Transcriptomics and proteomics
RNA-seq and proteomics measure expression changes in lipogenic enzymes and regulators. Ketohexokinase-C regulation of global protein acetylation was uncovered using proteomics.
Functional assays for ferroptosis and insulin sensitivity
Ferroptosis assays (e.g., lipid peroxidation, cell viability) and insulin sensitivity tests in hepatocytes or mice are used to link negative regulation of lipid biosynthesis to disease phenotypes [1,5].
How CRISPR Can Be Used to Study GO:0051055 negative regulation of lipid biosynthetic process
Knockout
CRISPR knockout of candidate negative regulators such as SCD1 or NCOA4 can confirm their role in restraining lipid biosynthesis. For instance, SCD1 knockout increases ferroptosis sensitivity in triple-negative breast cancer cells.
Point Mutation
Introducing point mutations in enzymes like lipid A biosynthetic proteins can dissect catalytic residues or regulatory phosphorylation sites, revealing mechanisms of feedback inhibition.
Knock-in
Knock-in of tagged versions of proteins such as Smoothened or KHK-C allows tracking of localization and interactions in vivo, providing insights into their regulatory functions [4,5].
Overexpression
Overexpression of negative regulators like YhcB in bacteria or NCOA4 in cancer cells can suppress lipid biosynthesis and alter disease phenotypes, validating their function [1,8].
How EDITGENE Supports negative regulation of lipid biosynthetic process Research
Researchers studying negative regulation of lipid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in restraining lipogenesis or is merely correlated with changes in lipid abundance. CRISPR-based models provide the gold standard for establishing causality, and EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipid biosynthetic process research.
Frequently Asked Questions About negative regulation of lipid biosynthetic process
What is negative regulation of lipid biosynthetic process?
It is any process that stops, prevents, or reduces the frequency, rate or extent of lipid biosynthesis, as defined by GO:0051055.
What genes are involved in negative regulation of lipid biosynthetic process?
Key genes include SCD1, NCOA4, SMO, KHK-C, and YhcB, among others [1,4,5,8].
How does SCD1 regulate lipid biosynthesis?
SCD1 catalyzes fatty acid desaturation; its inhibition reduces lipogenesis and sensitizes cancer cells to ferroptosis.
What is the role of NCOA4 in lipid metabolism?
NCOA4 mediates ferritinophagy, affecting iron availability and lipid peroxidation, which influences lipogenesis and ferroptosis.
How is negative regulation of lipid biosynthesis linked to NAFLD?
Hepatocyte Smoothened activity and KHK-C-mediated acetylation control hepatic lipogenesis and insulin resistance, contributing to NAFLD [4,5].
Can CRISPR be used to study negative regulation of lipid biosynthetic process?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to dissect gene function in lipid biosynthesis [1,4,5].
What experimental models are suitable for studying this process?
Cell lines, primary hepatocytes, and mouse models with liver-specific knockouts are commonly used [4,5,6].
What is the connection between gut microbiota and lipid biosynthesis?
Diet and gut microbiota interact with host genetics to regulate lipid metabolism and obesity.
How do intestine-derived exosomes regulate hepatic lipid metabolism?
Exosomes from intestinal epithelium can suppress hepatic lipogenesis, representing inter-organ communication.
What are the therapeutic implications of targeting negative regulators of lipogenesis?
Modulating these regulators can induce ferroptosis in cancer and improve metabolic disease outcomes [1,5].
Conclusion
GO:0051055, negative regulation of lipid biosynthetic process, is a critical biological process that maintains lipid homeostasis and prevents disease. Its dysregulation is implicated in cancer, NAFLD, insulin resistance, and acne, making it a rich area for therapeutic targeting [1,2,4,5]. Advances in CRISPR technology and multi-omics approaches are accelerating the discovery of new regulators and their mechanisms. EDITGENE provides the tools and expertise to support this research, from knockout cell lines to bioinformatics analysis.
References
- 1. Huang G et al.. 2025. Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy.. J Adv Res 74:589-607 PMID: 39353532
- 2. Melnik BC. 2015. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update.. Clin Cosmet Investig Dermatol 8:371-88 PMID: 26203267
- 3. Cuevas-Sierra A et al.. 2019. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications.. Adv Nutr 10(suppl_1):S17-S30 PMID: 30721960
- 4. Helsley RN et al.. 2023. Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation.. J Hepatol 79(1):25-42 PMID: 36822479
- 5. Chen T et al.. 2023. Hepatocyte Smoothened Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver Disease.. Cell Mol Gastroenterol Hepatol 15(4):949-970 PMID: 36535507
- 6. Feng T et al.. 2023. Regulation of hepatic lipid metabolism by intestine epithelium-derived exosomes.. Life Metab 2(6):load044 PMID: 39872853
- 7. Zhou P et al.. 2017. Structure, inhibition, and regulation of essential lipid A enzymes.. Biochim Biophys Acta Mol Cell Biol Lipids 1862(11):1424-1438 PMID: 27940308
- 8. Stanley HM et al.. 2024. Loss of YhcB results in overactive fatty acid biosynthesis.. mBio 15(6):e0079024 PMID: 38742872
